RARRES3 Human shRNA Plasmid Kit (Locus ID 5920)
CAT#: TL320510
RARRES3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
Cited in 1 publication. |
Product images
CNY 6,281.00
CNY 4,070.00
Specifications
Product Data | |
Product Name | RARRES3 Human shRNA Plasmid Kit (Locus ID 5920) |
Locus ID | 5920 |
UniProt ID | Q9UL19 |
Synonyms | HRASLS4; HRSL4; PLA1/2-3; PLAAT-4; RARRES3; RIG1; TIG3 |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | RARRES3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 5920). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_004585, NM_004585.1, NM_004585.2, NM_004585.3, NM_004585.4, BC009678, BC009678.1, NM_004585.5 |
Summary | Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of hyperproliferative dermatological diseases. These effects are mediated by specific nuclear receptor proteins that are members of the steroid and thyroid hormone receptor superfamily of transcriptional regulators. RARRES1, RARRES2, and RARRES3 are genes whose expression is upregulated by the synthetic retinoid tazarotene. RARRES3 is thought act as a tumor suppressor or growth regulator. [provided by RefSeq, Jul 2008] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
RARRES3 suppressed metastasis through suppression of MTDH to regulate epithelial-mesenchymal transition in colorectal cancer
,Wang, Z;Wang, L;Hu, J;Fan, R;Zhou, J;Wang, L;Zhong, J;,
Am J Cancer Res
,PubMed ID 26269758
[PLAAT4]
|
Documents
Product Manuals |
FAQs |
SDS |